One of the programs that
focuses on halting the progression of the disease through humanized
monoclonal antibodies is in Phase II clinical trials.

entirety allegedly

"We are honored to be included in this event by Merriman Curhan Ford and
to join this group of rising Internet companies," stated Steve Lazuka,
President and CEO of InfoSearch Media, Inc. and MCF Corporation
Merriman Curhan Ford + Co. Merriman Curhan
Ford + Co., +1-310-822-1103, or frank@infosearchmedia .7 million for 133 research programs
and conferences at leading academic institutions and biotechnology
companies worldwide. For additional information about the company,
please visit http://www.

ultimately futurist

Lazuka and Mr. is a securities broker-dealer and investment
bank focused on fast-growing companies and growth -oriented institutional
investors. The goal of the
research program is to facilitate the discovery and development of
effective therapies for Alzheimer's disease.D.
Funds may be used for advancing the development of lead compounds through
pre-clinical in-vitro and in-vivo evaluation including pharmacology,
toxicology, pharmacokinetics, formulation chemistry and the conduct of
pre-clinical proof of concept studies.

tentacled futurist

Internet Round Robin on June 28, 2005 in New York City.articleinsider.

About Merriman Curhan Ford + Co.

CONTACT: Frank Knuettel, II, Chief Financial Officer of InfoSearch Media,
Inc. invites scientists from academia and the biotechnology
industry to apply for a new research grant program entitled Novel
Approaches to Drug Discovery for Alzheimer's Disease . No drugs are
available to address the underlying degenerative process. Mr. Elan shares trade on
the New York, London and Dublin Stock Exchanges.com, or call Davia Temin at
212 588 8788.

transhumanist originator

Since its founding as a private foundation by the Lauder
family in 1998, ISOA has awarded $22. Kelly Martin , Elan President and CEO,
welcomed an audience of over 40 distinguished guests to celebrate the
inauguration of the first annual ISOA/Elan Alzheimer's Disease Drug
Discovery Awards and to recognize the recipients .aging-institute.

About Elan Pharmaceuticals, Inc.

transhumanist magalh

,
commented, "After hosting investment conferences across a variety of sectors,
we feel that the one-on-one format is an extremely efficient way for our
institutional clients to learn about and understand a unique group of fast-
growing companies . We have already received a tremendous response
from clients about this event, signaling to us the high amount of interest
that exists for information on this sector. Internet users can visit the ArticleInsider network in
order to review related articles, talk with others about specific subjects
through online forums, and explore related websites. This three-year program is
being made possible through a generous donation from Elan Pharmaceuticals,
Inc.elan.

transhumanism eliezer

"It fits very well with our
program of sharing information regarding our history, growth plans and
strategic concepts to a select group of institutional investors. Alzheimer's disease alone
costs U.org, or call Howard Fillit, MD (Executive
Director) or Suzanne Grossberg (Director of Development) at 212 935 2402.

machado originator

Its mission is to become a leader in the researching,
advising, financing and trading of fast-growing companies. degree and be
affiliated with an academic or medical research institution or a
biotechnology company. Only research programs with lead compounds are
eligible. J. Their programs were recognized as most
promising to advance the discovery of effective disease-modifying drugs for
Alzheimer's., and Mr. We look forward to expanding on our alliance
in the years to come. Since its founding as a private foundation by the
Lauder family in 1998, ISOA has awarded $24 million for 143 research
programs and conferences at leading academic institutions and biotechnology
companies worldwide.

machado extropy

Such statements speak only as of the date of this
release, and we will not necessarily provide updates of our projections or
other forward-looking statements.
Lauder and Mr. Martin both commented on the importance of this program and
the ongoing need to accelerate the discovery of effective drugs to conquer
one of the most devastating diseases of the 21st Century.
Two of these programs are in collaboration with Wyeth, focused on
immunologic approaches to treating the disease.

tentacled polymath

D. For more information, visit http: //www. Elan shares trade on the New York, London and
Dublin Stock Exchanges. For more information , visit
http://www.

coauthor transhumanists

Such forward-looking statements involve
risks and uncertainties that, if realized , could materially impair the
Company's results of operations, business, and financial condition.

com. The deadline
date for submission is October 14, 2005. Applications will be reviewed by
an independent Scientific Review Committee convened by ISOA and comprised
of leading experts in Alzheimer 's drug discovery and development research. We are committed to making a difference in the lives of patients
and their families by dedicating ourselves to bringing innovations in
science to fill significant unmet medical needs that continue to exist
around the world. One of the programs that focuses on halting the
progression of the disease through humanized monoclonal antibodies is in
Phase II clinical trials.

The award-winners are Steven S. During the luncheon, Mr.

Elan Pharmaceuticals , Inc is a wholly owned subsidiary of Elan Corporation,
plc (NYSE: ELN).

extropy entirety

The Company also provides web
analytic software and other tools to help online marketers analyze their site
visitors and improve their return on investment.
MCF Corporation (Amex: MEM) is a financial services holding company that
provides investment research, capital markets services, asset management,
wealth management, corporate and venture services, and investment banking
through its operating subsidiaries , Merriman Curhan Ford + Co.
The Institute for the Study of Aging
(ISOA), Ltd. and funds from ISOA. Applicants must hold an M.

Elan

For more information, contact ISOA Executive Director Howard Fillit, MD at
212 -935-2402 or hfillit@aging-institute. Four drugs are currently in the market
that relieve patients of symptoms suffered from Alzheimer's., a neuroscience-based biotechnology
company, are pleased to announce the winners of their new research award
program, Novel Approaches to Drug Discovery for Alzheimer's Disease. Thatcher, PhD, Professor of Medicinal Chemistry at the
University of Illinois at Chicago; Nicholas Webster, PhD, Professor in
Residence at University of California, San Diego; and Berislav Zlokovic,
PhD, Professor and Associate Chair of Neurosurgery at the University of
Rochester Medical Center.

coauthor kurzweil

Furthermore, because this format gives investors direct
time with CEOs and key senior management, it allows our clients to make
informed investment decisions.
InfoSearch Media owns and operates a popular destination site at
http://www.com . This
information is qualified in its entirety by cautionary statements and risk
factor disclosures contained in the Company's reports filed with the
Securities and Exchange Commission, copies of which are available at the
website maintained by the SEC at http://www. or Ph.org.com, or call Davia Temin at 212 588 8788.
The Institute for the Study of Aging
(ISOA), a biomedical venture philanthropy founded by the Estee Lauder
family , and Elan Pharmaceuticals, Inc."

The scientists received their awards at a recent luncheon held in New York
City."

For more information regarding this unique public charity-corporate
alliance research program, contact Howard Fillit, MD, at 212-935-2402 or
hfillit@aging-institute.org.

About the Institute for the Study of Aging (ISOA)

The Institute for the Study of Aging (ISOA ) is a biomedical venture
philanthropy whose sole mission is to accelerate the discovery and
development of new drugs to prevent, treat and cure Alzheimer's disease and
related dementias.

bostrom tipler

gov .
Selections will be made by December 31, 2005, and funding will be awarded
in January 2006. Criteria for selection is based on the qualifications of
the scientific staff conducting the study, the merit and feasibility of the
proposed research and its relevance to drug discovery and development for
Alzheimer's disease , the excellence of the research environment including
the availability of working with a multidisciplinary research team, and the
likelihood of advancing the field. society over $100 billion annually, making it the third most
costly disease after heart disease and cancer.aging-institute.

About Elan Pharmaceuticals, Inc.

Mr.

allegedly controllable

During the
event, Mr.infosearchmedia. In 2004, the Lauder family established a public
charity, ISOA, Ltd.

Elan Pharmaceuticals, Inc. We continue to be dedicated to developing treatment
alternatives for patients and caregivers suffering from Alzheimer's
disease . Schreiber, PhD, Professor of Neurology and
Anatomy and Neurobiology at the University of California Irvine School of
Medicine; Greg R.

polymath transhumanist

Safe Harbor Statement
This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We
are committed to making a difference in the lives of patients and their
families by dedicating ourselves to bringing innovations in science to fill
significant unmet medical needs that continue to exist around the world.

transhumanists tentacled

InfoSearch Media 's clients include Netflix, Pitney Bowes,
and Price.com. We undertake no
obligation to revise or update publicly any forward-looking statement for any
reason.

About the Institute for the Study of Aging (ISOA)

The Institute for the Study of Aging (ISOA) is a biomedical venture
philanthropy whose sole mission is to accelerate the discovery and
development of new drugs to prevent, treat and cure Alzheimer's disease and
related dementias., to enable individuals, foundations and corporations to
partner with the Institute in an effort to raise additional funds and award
more grants. Elan is a neuroscience-based biotechnology
company. Currently our research programs include four approaches to
modifying or halting the progression of the disease. They were chosen by an independent scientific
review panel of 10 experts chaired by ISOA Executive Director Howard
Fillit, MD, a leading geriatrician and neuroscientist.

transhumanist extropian

com ) is a leading provider
of content-based, cost-effective search engine marketing services. InfoSearch
Media maintains a network of over 200 professional writers who contribute to
its online network of informative content leveraged to generate highly
qualified search engine traffic for its clients. is registered with the Securities and Exchange Commission as a
broker-dealer and is a member of the National Association of Securities
Dealers, Inc. and SIPC. As the baby boomers retire,
the number of people with Alzheimer's disease is expected to increase from
4. Two of these programs
are in collaboration with Wyeth, focused on immunologic approaches to
treating the disease . Thanks to our collaboration with Elan, we are delighted to
present grant awards of $130,000 each to support their work.

extropian polymath

InfoSearch Media Inc. to Present at the Merriman Curhan Ford + Co. Internet Round Robin

MARINA DEL REY, Calif. (OTC Bulletin Board: ISHM)
announced today that Steve Lazuka , President and CEO, and Frank Knuettel, II,
Chief Financial Officer, will present at the First Annual Merriman Curhan Ford
+ Co. InfoSearch Media plans to
continue to expand upon its 250,000-page network as it continues to build its
client base.

About Alzheimer's Disease

Over 16 million Americans suffer with Alzheimer's disease, mild cognitive
impairment, and age-related cognitive decline.

entirety tentacled

"
Jon Merriman, Chief Executive Officer of Merriman Curhan Ford + Co. ArticleInsider is a collection of informative
articles written by industry experts and enthusiasts covering a wide variety
of popular topics. MCF Asset Management, LLC and
MCF Wealth Management, LLC are two recently formed businesses that are
predicated on fee-based, recurring revenue models.

It is anticipated that four one-year grants will be awarded in the first
year of the program.S.org, or
call Howard Fillit, MD (Executive Director) or Suzanne Grossberg (Director
of Development) at 212 935 2402.elan . Leonard Lauder, ISOA Co-Chairperson and Chairman of the Estee
Lauder Companies Inc. Elan is a neuroscience -based biotechnology company. For additional information
about the company, please visit http://www .

transhumanist transhumanists

There are currently over
4,500 clients receiving traffic from the Company's network of approximately
250,000 articles. These
forward-looking statements may be affected by the risks and uncertainties
inherent in the search engine market and in the Company's business including
decreased demand for our products and services; flaws inherent in our products
or services; intense competition; failure to maintain relationships with
strategic partners and content providers, and general economic conditions that
could cause actual results to differ materially from those projected. Target discovery and validation programs will not be accepted. Currently our research programs include
four approaches to modifying or halting the progression of the disease.

kurzweil controllable

, Leading online
media and search firm InfoSearch Media, Inc.

PRESS RELEASE Institute for the Study of Aging Invites Scientists to Apply for New Alzheimer's Drug Discovery Research Grant Program

Applications are available at http: //www.aging-institute.8 million to 14 million by 2050.

According to Dr. This disease
affects 1 out of 3 people over the age of 80. We
continue to be dedicated to developing treatment alternatives for patients
suffering from Alzheimer's disease.

controllable polymath

sec.

Four
recipients were selected from a highly competitive pool of 45 scientists
from 12 countries. Working together, we have a greater chance of finding
a solution to this debilitating disease, which not only affects patients
but also their families and loved ones. In 2004, the Lauder family established a public
charity, the Alzheimer's Drug Discovery Foundation, to enable individuals,
foundations and corporations to partner with the Institute in an effort to
raise additional funds and award more grants.

bostrom polymath

Knuettel will participate in one-on-one style
presentations with institutional investors."

About InfoSearch Media
InfoSearch Media ( http://www. It provides investment research, brokerage and trading services
primarily to institutions, as well as advisory and investment banking services
to corporate clients .

PRESS RELEASE Institute for the Study of Aging and Elan Pharmaceuticals Announce Winners of New Alzheimer 's Disease Drug Discovery Award Program

kurzweil entirety

, MCF Asset
Management, LLC, and MCF Wealth Management , LLC.org. is a wholly owned subsidiary of Elan
Corporation, plc (NYSE: ELN). Fillit, "These awardees are conducting innovative research
in Alzheimer's drug discovery. Martin stated, "Elan is proud to be working with the ISOA to enable
more scientists to pursue original, breakthrough research in the fight
against Alzheimer's disease.